Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Kashiv BioSciences, LLC
EIR
•Kashiv BioSciences, LLC•March 12, 2019

Kashiv BioSciences, LLC – FDA EIR, Mar 12, 2019

Record Details

A pre-licensing FDA inspection of Kashiv Biosciences (formerly Adello Biosciences) was conducted from March 4-12, 2019. The inspection, which evaluated the company's readiness for manufacturing, testing, and secondary packaging of Theragrastim (Filgrastim biosimilar) under applicable regulations for drug product manufacturing and pre-approval processes, uncovered significant deficiencies. A seven-item Form FDA 483 was issued. Key violations included the Quality Unit's failure to adhere to responsibilities, such as proper review of batch disposition records, and its inability to establish adequate procedures. The FDA also cited failures in adhering to laboratory control procedures, establishing the reliability of laboratory methods, and conducting thorough investigations. Additionally, issues were noted with the appropriate storage and handling of cell banks and reference materials, as well as establishing incoming controls for components. Investigators highlighted the repeat nature of several observations, indicating persistent quality oversight concerns, especially following prior deficiencies in 2017 and 2018 that led to a 'Withhold' decision. Kashiv Biosciences management acknowledged the seriousness of the findings, promising a written response within 15 working days and initiating some corrective actions during the inspection, with the CEO verbally committing to necessary changes.

Company
Kashiv BioSciences, LLC
Inspection date
March 12, 2019
Product type
biologics
Office
Chicago District Office
People
  • Rebecca E. Dombrowski
  • Vaishali J. Patel
  • Ramesh B. Potla
  • Rong Wang (investigator)
  • Steven Fong (Microbiologist)
View Company Profile

ID · 63ca7e5b-b9ab-4ca0-839c-56d3c240a043

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Kashiv BioSciences, LLC
  • 483 - 2024-06-14June 14, 2024
  • 483 - 2022-11-21November 21, 2022
  • 483 - 2022-01-14January 14, 2022
  • 483 - 2019-03-12March 12, 2019
  • 483 - 2018-01-22January 22, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kashiv BioSciences, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.